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• 
Chronic rhinosinusitis w
ith nasal polyps (CRSw
NP) is a chronic inflam
m
atory disease of the nasal and 
paranasal sinuses associated w
ith high sym
ptom
 burden and poor health-related quality of life (HRQoL)
• 
CRSw
NP predom
inantly displays a type 2 inflam
m
atory signature w
ith interleukin (IL)-4, IL-5, and  
IL-13 as prom
inent cytokines, and tissue infiltration by eosinophils, basophils, and m
ast cells
1,2
• 
Available treatm
ents options for CRSw
NP, lim
ited to the chronic use of intranasal corticosteroids (INCS), 
short courses of system
ic corticosteroids (SCS) w
hen sym
ptom
s w
orsen, and surgery w
hen m
edication 
fails, do not address the underlying sinus inflam
m
atory disease
• 
Dupilum
ab is a fully hum
an VelocIm
m
une
®-derived m
onoclonal antibody
3,4  that blocks the shared receptor 
subunit for IL-4 and IL-13, key drivers of type 2 inflam
m
ation
5 
• 
Dupilum
ab is approved in the USA for patients aged ≥ 12 years w
ith m
oderate-to-severe eosinophilic 
or oral corticosteroid-dependent asthm
a
6–8 and for the treatm
ent of adults w
ith inadequately controlled 
m
oderate-to-severe atopic derm
atitis in several countries
9–11
• 
In a phase 2a proof-of-concept study (ClinicalTrials.gov Identifier: NCT01920893), dupilum
ab on a 
background of m
om
etasone furoate nasal spray (M
FNS) significantly im
proved endoscopic, radiographic, 
clinical, and patient-reported outcom
es in patients w
ith CRSw
NP refractory to INCS
12
• 
The phase 3 study SINUS-52 (NCT02898454) w
as conducted to further investigate dupilum
ab  
efficacy and safety in treating patients w
ith severe CRSw
NP uncontrolled by standard of care
O
B
J
E
C
T
IV
E
• 
To evaluate the efficacy and safety of dupilum
ab com
pared w
ith placebo in patients w
ith 
CRSw
NP receiving M
FNS background therapy
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• 
In patients w
ith severe uncontrolled CRSw
NP, dupilum
ab as add-on to M
FNS significantly 
im
proved all disease com
ponents tested (nasal polyp size, sinus opacification, rhinosinusitis 
sym
ptom
s), reduced anosm
ia, and im
proved HRQoL
 –
Im
provem
ents in all outcom
e m
easures w
ere noted early in treatm
ent (at the first assessm
ent 
tim
e point) and continued to im
prove across the 52-w
eek treatm
ent period
• 
Dupilum
ab reduced system
ic steroid use and the need for NP surgery
• 
Dupilum
ab im
proved lung function and asthm
a control in CRSw
NP patients w
ith com
orbid 
asthm
a, a difficult-to-treat patient population 
• 
Overall, the 300 m
g q2w
 regim
en had better sustained im
provem
ents in the objective m
easures 
of NPS and LM
K-CT scan score and few
er breakthrough TEAEs of w
orsening of nasal polyps, 
asthm
a, and sinusitis than the 300 m
g q2w
–q4w
 regim
en
• 
Dupilum
ab w
as w
ell tolerated
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Figure 1. S
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U
S
-52 study (C
linicalTrials.gov  
Identifier: N
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T02898454).
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Study design
• 
The design of this m
ultinational, m
ulticenter, random
ized, double-blind, phase 3, placebo-controlled, 
parallel-group study is show
n in Figure 1
• 
Patients received a background therapy of 400 µg M
FNS daily
• 
Patients w
ere random
ized 1:1:1 as follow
s:
 –
Arm
 A: SC dupilum
ab 300 m
g q2w
 until W
eek 52
 –
Arm
 B: SC dupilum
ab 300 m
g q2w
 until W
eek 24 follow
ed by 300 m
g q4w
 until W
eek 52 
 –
Arm
 C: placebo m
atching SC dupilum
ab q2w
 until W
eek 52
• 
Rescue treatm
ent w
ith system
ic corticosteroids, NP surgery, saline nasal lavage, and system
ic antibiotics 
w
as allow
ed at the investigator’s discretion
• 
The patient population w
as stratified for com
orbid asthm
a/AERD (aspirin and nonsteroidal anti-
inflam
m
atory drug-exacerbated respiratory disease) and prior NP surgery 
M
ain inclusion criteria
• 
Adult patients aged ≥ 18 years w
ho have undergone prior treatm
ent w
ith or have contraindication/
intolerance to SCS in the past 2 years, or have had prior surgery for NPs, w
ith bilateral endoscopic nasal 
polyp score (NPS) ≥ 5 (out of 8), w
ith ≥ 2 for each nostril
• 
2 or m
ore of the follow
ing rhinosinusitis sym
ptom
s:
 –
Nasal obstruction (sym
ptom
 severity score of 2 or 3), AND
 –
Rhinorrhea (anterior/posterior) OR
 –
Reduction or loss of sm
ell
M
ain exclusion criteria
• 
M
onoclonal antibody and im
m
unosuppressant treatm
ent w
ithin 2 m
onths or anti-IgE therapy (om
alizum
ab) 
w
ithin 130 days before screening
• 
Sinus surgery (including polypectom
y) w
ithin 6 m
onths before screening or sinonasal surgery changing 
the lateral w
all structure of the nose, m
aking the evaluation of NPS im
possible
• 
Patients w
ith forced expiratory volum
e in 1 second (FEV
1 ) ≤ 50%
 of predicted norm
al
A
ssessm
ent
• 
Co-prim
ary efficacy endpoints
 –
Change from
 baseline in endoscopic NPS at W
eek 24 for dupilum
ab (pooled Arm
 A+B) vs placebo
 –
Change from
 baseline in patient-reported nasal congestion (NC) score at W
eek 24 for dupilum
ab 
(pooled Arm
 A+B) vs placebo
• 
Key secondary endpoints
 –
Change from
 baseline in sinus opacification using sinus com
puted tom
ography Lund–M
ackay 
(LM
K-CT) score for dupilum
ab (pooled Arm
 A+
B) vs placebo at W
eek 24
 –
Change from
 baseline in patient-reported total sym
ptom
 score (TSS), University of Pennsylvania Sm
ell 
Identification Test (UPSIT) score, daily loss-of-sm
ell score, and 22-item
 Sino-Nasal Outcom
e Test 
(SNOT-22) score at W
eek 24 for dupilum
ab (pooled Arm
 A+B) vs placebo 
 –
Change from
 baseline in endoscopic NPS, NC score, and SNOT-22 score at W
eek 52 for dupilum
ab 
(Arm
 A) vs placebo
Table 1. Baseline dem
ographics and clinical characteristics of treatm
ent groups.
Placebo
(n = 153)
Dupilum
ab
300 m
g q2w
  
(n = 150)
300 m
g q2w
–q4w
  
(n = 145)
Age, years; m
ean (SD)
51.67 (12.66)
51.91 (11.88)
52.28 (12.87)
M
ale, n (%
) 
95 (62.1)
97 (64.7)
87 (60.0)
NP duration, years; m
ean (SD)
10.88 (9.40)
11.28 (10.38)
10.67 (9.12)
 
Patients w
ith ≥ 1 prior surgery, n (%
)
88 (57.5)
88 (58.7)
85 (58.6)
 
 Patients w
ith SCS use in the previous 2 years, n (%
)
122 (79.7)
121 (80.7)
116 (80.0)
Patients w
ith any com
orbid type 2 m
edical history 
including asthm
a/AERD, n (%
)
127 (83.0)
122 (81.3)
120 (82.8)
 
Patients w
ith com
orbid asthm
a
91 (59.5)
85 (56.7)
91 (62.8)
 
Patients w
ith com
orbid AERD
44 (28.8)
35 (23.3)
41 (28.3)
Bilateral endoscopic NPS, a range 0–8; m
ean (SD)
5.96 (1.21)
6.07 (1.22)
6.29 (1.20)
Daily NC score, a range 0–3; m
ean (SD)
2.38 (0.54)
2.48 (0.62)
2.44 (0.59)
LM
K-CT score, a range 0–24; m
ean (SD)
17.65 (3.76)
18.42 (3.61)
17.81 (3.89)
TSS, a range 0–9;  m
ean (SD)
7.08 (1.38)
7.31 (1.41)
7.28 (1.55)
Sm
ell test (UPSIT) score, a range 0–40; m
ean (SD)
13.78 (8.31)
13.46 (8.20)
13.60 (7.57)
Loss of sm
ell (daily, m
orning) score, a range 0–3; m
ean (SD) 
2.72 (0.52)
2.81 (0.46)
2.73 (0.59)
SNOT-22 total score, a range 0–110; m
ean (SD)
53.48 (21.85)
50.16 (19.72)
51.89 (21.05)
CRSw
NP severity (VAS) score, a range 0–10 cm
; m
ean (SD)
7.98 (2.22)
8.24 (1.77)
7.78 (2.20)
Blood eosinophils, Giga/L; m
ean (SD)
0.45 (0.36)
0.45 (0.39)
0.40 (0.30)
Total serum
 IgE, IU/m
L; m
ean (SD)
227.80 (267.13)
210.82 (256.78)
282.28 (463.72)
In patients w
ith asthm
a
 
FEV
1 , L; m
ean (SD)
2.58 (0.80)
2.53 (0.91)
2.59 (0.78)
 
FEV
1 , %
 predicted; m
ean (SD)
83.46 (16.64)
82.47 (20.92)
84.18 (15.51)
 
ACQ-6 score, a range 0–6; m
ean (SD)
1.63 (1.03)
1.45 (0.99)
1.65 (1.23)
aHigher scores indicate greater disease severity except for UPSIT, w
here higher scores indicate low
er disease severity.  
SD, standard deviation; VAS, Visual Analog Scale.
Table 2. Treatm
ent-em
ergent adverse events.
Patients w
ith TEAEs, a n (%
)
Placebo
(n = 150)
Dupilum
ab
300 m
g q2w
(n = 149)
300 m
g q2w
–q4w
(n = 148)
Any TEAE
136 (90.7)
124 (83.2)
132 (89.2)
Any serious TEAE
15 (10.0)
8 (5.4)
10 (6.8)
Any TEAE leading to death
0
0
1 (0.7)
Any TEAE leading to perm
anent treatm
ent discontinuation
17 (11.3)
6 (4.0)
2 (1.4)
TEAEs occurring in ≥ 5%
 of patients (M
edDRA PT)
Nasopharyngitis
36 (24.0)
30 (20.1)
31 (20.9)
Upper respiratory tract infection
19 (12.7)
10 (6.7)
8 (5.4)
Bronchitis 
8 (5.3)
9 (6.0)
9 (6.1)
Sinusitis
17 (11.3)
8 (5.4)
13 (8.8)
Headache 
18 (12.0)
14 (9.4)
16 (10.8)
Nasal polyps 
25 (16.7)
8 (5.4)
15 (10.1)
Epistaxis 
20 (13.3)
13 (8.7)
7 (4.7)
Cough
8 (5.3)
9 (6.0)
9 (6.1)
Asthm
a 
19 (12.7)
6 (4.0)
13 (8.8)
Injection-site erythem
a
11 (7.3)
11 (7.4)
10 (6.8)
Injection-site reaction
3 (2.0)
5 (3.4)
8 (5.4)
aDefined as events occurring from
 the first adm
inistration of study m
edication to the end of the post-treatm
ent period by M
edical Dictionary for 
Regulatory Activities Preferred Term
 (M
edDRA PT).
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Figure 2. D
upilum
ab treatm
ent (300 m
g q2w
 and 300 m
g q2w
–q4w
) vs placebo significantly im
proved N
P
S
 and N
C
 score in the ITT population, over the 52-w
eek treatm
ent 
period.
***P < 0.0001 for dupilum
ab vs placebo. P < 0.0001 for dupilum
ab 300 m
g q2w
 and 300 m
g q2w
–q4w
 vs placebo at all tim
e points. CI, confidence interval; LS, least squares; SE, standard error.
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Figure 3. D
upilum
ab treatm
ent (300 m
g q2w
 and 300 m
g q2w
–q4w
) vs placebo im
proved clinical and patient-reported outcom
es in the ITT population.
***P < 0.0001 for dupilum
ab vs placebo. P < 0.0001 for dupilum
ab 300 m
g q2w
 and 300 m
g q2w
–q4w
 vs placebo at all tim
e points. For SNOT-22 score, differences > 8.9 are considered clinically relevant.
• 
The follow
ing additional endpoints w
ere also evaluated:
 –
Proportion of patients during study treatm
ent w
ho received SCS and/or had surgery for NP
 –
For patients w
ith com
orbid asthm
a, change from
 baseline to W
eek 24 in lung function (FEV
1  [L]), and 
asthm
a control, m
easured by the 6-item
 Asthm
a Control Questionnaire (ACQ-6)
• 
Safety
 –
Incidence of treatm
ent-em
ergent adverse events (TEAEs) and serious adverse events
Statistical m
ethods
• 
Each of the 2 co-prim
ary efficacy endpoints and the key secondary endpoints w
ere prospectively 
defined and m
ultiplicity adjusted, and w
ere analyzed using a hybrid m
ethod of the w
orst-observation 
carried forw
ard and m
ultiple im
putation m
ethods
• 
Pooling of treatm
ent arm
s for efficacy analyses
 –
For analyses of change from
 baseline to W
eek 24, Arm
 A (300 m
g q2w
) w
as pooled w
ith Arm
 B 
(300 m
g q2w
–q4w
) as both groups w
ere receiving 300 m
g q2w
 up to W
eek 24
 –
The pooled Arm
 A+B w
as com
pared w
ith Arm
 C (placebo) at W
eek 24
 –
Arm
 A (300 m
g q2w
 for 52 w
eeks) and Arm
 B (300 m
g q2w
–q4w
) w
ere com
pared separately w
ith 
Arm
 C (placebo)
R
E
S
U
LT
S
Patients
• 
A total of 448 patients w
ere random
ized (intention-to-treat [ITT] population: Arm
 A, n = 150; Arm
 B,  
n = 145; Arm
 C, n = 153)
• 
Patient baseline dem
ographics and clinical characteristics w
ere com
parable betw
een treatm
ent groups 
and consistent w
ith a severe, uncontrolled CRSw
NP setting (Table 1)
• 
82.4%
 had type 2 com
orbid disease, including 59.6%
 w
ith asthm
a
(A
) D
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ab vs placebo increased FE
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Figure 5. D
upilum
ab treatm
ent (300 m
g q2w
 and 300 m
g q2w
–q4w
) im
proved lung 
function (A
) and asthm
a control (B
) in the ITT population, vs placebo, from
 baseline 
to W
eek 24.
*P < 0.01, **P < 0.001, ***P < 0.0001, dupilum
ab (300 m
g q2w
, 300 m
g q2w
–q4w
, and both treatm
ent groups pooled) vs placebo.
***P < 0.0001 for dupilum
ab (pooled treatm
ent groups) vs placebo. P < 0.0001 for dupilum
ab 300 m
g q2w
 and 300 m
g q2w
–q4w
 vs placebo 
at all tim
e points. Differences > 0.5 are considered clinically relevant. 
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• 
The m
ost com
m
on TEAE occurring at higher frequency in dupilum
ab-treated vs placebo-treated patients 
w
as injection-site reactions (Table 2)
• 
The m
ost com
m
on TEAE in all treatm
ent groups w
as nasopharyngitis (Table 2)
• 
Overall safety profile w
as com
parable betw
een the tw
o dupilum
ab regim
ens. How
ever, TEAEs of w
orsening 
of nasal polyps, asthm
a and sinusitis occurred w
ith a higher cum
ulative incidence in patients w
ho 
sw
itched at W
eek 24 from
 dupilum
ab 300 m
g q2w
 to q4w
 dosing com
pared w
ith those w
ho rem
ained 
on 300 m
g q2w
 for the full 52 w
eeks
• 
The m
agnitude of the additional im
provem
ents observed from
 W
eek 24 to 52 in NPS and sinus 
opacification (LM
K-CT score) w
ere num
erically greater in the patients w
ho continued on the 300 m
g 
q2w
 regim
en than those w
ho sw
itched to q4w
 dosing at W
eek 24 (NPS: −
0.53 and −
0.31 for 300 m
g 
q2w
 and 300 m
g q2w
–q4w
, respectively; LM
K-CT scan score: −
1.37 and −
0.62  for 300 m
g q2w
 and 
300 m
g q2w
–q4w
, respectively)
• 
Dupilum
ab reduced the proportion of patients requiring SCS or NP surgery vs placebo: hazard ratio (HR) 
[95%
 CI] 0.238 [0.156–0.364]; nom
inal P < 0.0001 (Figure 4)
 –
Dupilum
ab 300 m
g q2w
 vs placebo reduced the proportion of patients requiring SCS by 74.6%
  
(HR [95%
 CI] 0.254 [0.166–0.391]; nom
inal P < 0.0001) and the proportion of patients requiring NP 
surgery by 89.4%
 (HR [95%
 CI] 0.106 [0.024–0.475]; nom
inal P = 0.0033)
• 
In patients w
ith com
orbid asthm
a (59.6%
), dupilum
ab significantly increased FEV
1  and reduced 
ACQ-6 by W
eek 4, w
ith results sustained up to W
eek 24 (P <
 0.0001 vs placebo for both at all tim
e 
points) (Figure 5A and B)
C
o-prim
ary efficacy endpoints
• 
Dupilum
ab significantly reduced nasal polyp size (m
easured by NPS) and patient-reported severity of 
nasal congestion (determ
ined by NC score) from
 baseline at W
eek 24 (P < 0.0001 vs placebo for both) 
(Figure 2A–D)
K
ey secondary endpoints
• 
Dupilum
ab reduced sinus opacification, m
easured by LM
K-CT score, from
 baseline at W
eeks 24 and 
52 (P <
 0.0001 vs placebo for all) (Figure 3A)
• 
Dupilum
ab reduced sym
ptom
s and im
proved HRQoL (assessed by TSS and SNOT-22 score), and also 
significantly im
proved sense of sm
ell (assessed by daily loss-of-sm
ell score and UPSIT score) from
 
baseline at W
eeks 24 and 52 (P <
 0.0001 vs placebo for all) (Figure 3B–E)
• 
In the dupilum
ab arm
, there w
as a reduction in the proportion of patients w
ith anosm
ia, determ
ined by 
UPSIT score, from
 79%
 at baseline to 30%
 at W
eek 24 com
pared w
ith no change in the placebo arm
• 
Dupilum
ab reduced NPS, NC score, and SNOT-22 score w
ith nom
inal significance from
 baseline at 
W
eek 52 (P <
 0.0001 vs placebo for all) (Figure 2A–D and 3C)
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Figure 4. D
upilum
ab treatm
ent (300 m
g q2w
 pooled) vs placebo reduced the need for 
S
C
S
 use and/or N
P
 surgery in the ITT population over the 52-w
eek treatm
ent period. 
Dupilum
ab treatm
ent group here is dupilum
ab treatm
ent Arm
s A+B pooled (first 24 w
eeks only for Arm
 B).
